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REVIEW

Nutritional Approaches to Achieve Weight Loss in
Nonalcoholic Fatty Liver Disease1–3
Christine C Hsu,4* Erik Ness,6 and Kris V Kowdley5
4

Division of Gastroenterology, University of Pennsylvania, Philadelphia, PA; and 5Swedish Liver Care Network, Swedish Medical Center, Seattle, WA

ABSTRACT

Nonalcoholic fatty liver disease (NAFLD) can range in spectrum from simple hepatic steatosis to nonalcoholic steatohepatitis (NASH), which is
characterized by lipotoxicity, hepatocellular ballooning, and inﬂammation and can progress to cirrhosis. Weight loss is the cornerstone treatment
for NAFLD and NASH. Various randomized controlled trials have shown that weight loss of $5–10% leads to significant improvements in hepatic
steatosis. Diets high in sodium and fructose have been implicated in the pathogenesis of NAFLD. Although some clinical studies suggest that an
isocaloric high-fructose diet does not worsen NAFLD, these clinical studies are often short in duration. More recently, the Dietary Approaches to
Stop Hypertension diet, a sodium-restricted diet, has been associated with less prevalence of NAFLD and has been shown to improve NAFLD. In
addition, the Mediterranean diet has been promising in improving hepatic steatosis, and a larger randomized controlled trial is currently enrolling
subjects. For those who are unable to pursue weight loss through dietary approaches, bariatric surgery has been shown to improve hepatic
steatosis and steatohepatitis. This method has been variable in improving hepatic fibrosis. In conclusion, weight loss is crucial to the
improvement of NAFLD and NASH, and patients should attempt various diets in an attempt to achieve weight loss. Adv Nutr 2017;8:253–65.
Keywords: nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, liver disease, obesity, metabolic syndrome, type 2 diabetes, DASH diet,
bariatric surgery

Introduction
Nonalcoholic fatty liver disease (NAFLD)6 is defined as
evidence of hepatic steatosis by imaging or histology
and the absence of secondary causes of hepatic fat accumulation (1). NAFLD is further categorized based on histology, with nonalcoholic fatty liver characterized by hepatic
steatosis without evidence of hepatocellular injury, and
nonalcoholic steatohepatitis (NASH) defined as hepatic
steatosis with associated hepatocyte injury (e.g., ballooning)

and inflammation, with or without fibrosis (1). NAFLD
has more of a benign course, with <4% of cases progressing
to cirrhosis, whereas NASH has more of an aggressive course,
with 21–28% of cases progressing to cirrhosis (2).

NAFLD Incidence and Prevalence
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Incidence data are limited and variable worldwide for
NAFLD. In studies from Japan and England, the incidence
of NAFLD ranged from 18.5 to 31 cases/1000 person-years
(3, 4). Similarly, there are wide discrepancies between prevalence data, depending on the populations studied and definitions used. NAFLD has now become the most common
cause of abnormal liver tests in industrialized countries (5,
6). In the United States, when using NHANES III from
1988 to 1994, the overall prevalence of NAFLD and NASH
in the lean population was ;19% and ;3%, respectively
(7). Various studies that used ultrasound estimate prevalence rates in the general population to be from 13% to
46% (8–12). With the use of magnetic resonance spectroscopy in the Dallas Heart Study, an estimated NAFLD prevalence of 31% was noted in the general population, with
a higher prevalence in Hispanics (45%) than in whites and
blacks (33% and 24%, respectively) (6). A summary review
of prevalence data by Vernon et al. (12) estimates a US
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NAFLD prevalence rate in the general population of 30%,
with the rest of the world ranging from 6% to 35%,
with a median of 20%. NASH rates are lower, on the order
of 3–5% (12). The estimated worldwide prevalence is 20–
30% in Western countries and 5–18% in Asia (13).

Risk Factors for NAFLD
Nonmodiﬁable risk factors for disease progression include
age, race, genetic background, and baseline histology,
whereas modiﬁable factors include weight gain, insulin resistance, and diabetes (14, 15). An increasing prevalence
(66%) of bridging ﬁbrosis is observed if the patient’s age is
>50 y and he or she is obese or diabetic (14, 15). Increasing
age, male sex, and Hispanic ethnicity are associated with increased NAFLD prevalence (6, 11, 16–22). In a cohort of 400
subjects recruited from an army medical center, the overall
prevalence of NAFLD was 46%, but was highest in Hispanics
(58.3%), and lower in Caucasians (44.4%) and African
Americans (35.1%) (22). In this study, NAFLD patients
had a higher BMI, ate fast food more often, and exercised
less often than those without NAFLD (22).
Obesity, metabolic syndrome, and diabetes mellitus
play a central role in the development of and progression
to NASH. In 432 patients with histologically proven NAFLD,
NASH patients were more likely to be male, have a lower
hip-to-waist ratio, have higher aspartate aminotransferase
(AST) and alanine aminotransferase (ALT) concentrations,
have higher serum triglycerides and have lower HDL (23).
Patients with moderate to severe ﬁbrosis were more likely
to be male and Caucasian, have type 2 diabetes, and have
higher ALT and AST concentrations (23). The prevalence
of NAFLD and NASH was higher (74% and 22.2%, respectively) in diabetic patients (22). Similarly, Leite et al. (24)
showed a 69% prevalence of NAFLD in patients with type
2 diabetes. Obesity and NAFLD are also strongly correlated
(25–29).

Natural History
Adams et al. (30) demonstrated that NAFLD patients in
Olmsted County, Minnesota, were at increased mortality
compared with what is expected (HR: 1.34; 95% CI: 1.003,
1.76; P = 0.03), secondary to malignancy (28%), ischemic
heart disease (25%), and liver disease (13%). Liver disease
was the third-leading cause of death in NAFLD patients,
but only the thirteenth-leading cause in the general Minnesota population (30). Risk factors associated with increased
mortality included impaired fasting glucose, increased age,
and cirrhosis (30). NASH patients specifically have increased
mortality from liver-related issues (31–34). The prevalence
of cirrhosis (10.8% compared with 0.7%, respectively) and
liver-related mortality (7.3% compared with 0.9%, respectively) were significantly higher in a 15-y follow-up for
NASH patients than they were for NAFLD patients (34).
Another study further supported overall increased mortality in 229 NAFLD patients (HR: 1.29; 95% CI: 1.04, 1.59;
P = 0.02) in a mean follow-up of 26.4 y (35). NAFLD
patients were again shown to be at increased risk of
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cardiovascular disease (HR: 1.55; 95% CI: 1.11, 2.15;
P = 0.01), but also at increased risk of liver-specific mortality, including from hepatocellular carcinoma (HR: 6.55;
95% CI: 2.14, 20.03; P = 0.001), cirrhosis (HR: 3.2; 95%
CI: 1.05, 9.81; P = 0.041), and infections (HR: 2.71; 95%
CI: 1.02, 7.26; P = 0.046) (35). Advanced fibrosis and
not the nonalcoholic fatty liver disease activity score
(NAS; based on steatosis, hepatocyte ballooning, and
lobular inflammation) predicted increased liver specific
mortality (35). In a meta-analysis, NASH patients had accelerated fibrosis when compared with NAFLD patients
(1 stage over 7.1 y compared with 1 stage over 14.3 y, respectively) (36).

Pathophysiology
NAFLD is a result of an imbalance between hepatic TG production and export. Studies that use radioactive labeling
have shown that most of the hepatic FFAs arise from the lipolysis of visceral fat (60–80%) and de novo lipogenesis
(26%), rather than from dietary FFAs (37–39). Hepatic
FFA deposition further leads to lipotoxicity, hepatic inflammation, oxidative stress, activated apoptotic pathways, and
hepatic fibrogenesis (2). Visceral fat, and to a lesser degree
subcutaneous fat, can produce many of the adipocytokines
that drive the chronic inflammatory response seen in obesity
(40–42). The adipose tissue becomes a source of hormones
(such as leptin and adiponectin) or cytokines (TNF-a and
IL-6) that are important contributors in worsening the
FFA load, insulin resistance, and tissue injury (40). Increased
hepatic exposure of fat-derived TNF-a can inhibit adiponectin and promote steatosis, oxidative stress, and hepatic
inflammation and apoptosis (43). Klein et al. (44) illustrated
that visceral fat is a predominant producer of inflammatory
adipocytokines by showing that liposuction, which removes
exclusively subcutaneous fat, does not improve insulin resistance or affect concentrations of inflammatory mediators
such as adiponectin, TNF-a, or IL-6 (44). Therefore, treatment should be targeted at the metabolic obesity that is central to the pathology of NASH.

Weight Loss in NASH
Lifestyle modiﬁcations should be the foundation of any
treatment plan, with the goals of increased energy expenditure and decreased caloric intake. Dietary weight loss and
exercise have been examined in various studies. Because
most liver-related mortality is observed in NASH patients,
clinical trials are often targeted at NASH patients rather
than those with NAFLD. The NAS, a scoring system devised
by the NASH Clinical Research Network, is used in clinical
trials as an objective measure of histologic improvement.
The NAS is based on steatosis, lobular inﬂammation, and
hepatocyte ballooning, but it can vary signiﬁcantly even between pathologists.
Two randomized controlled trials illustrated the beneﬁts
of weight loss on histologic markers. Fifty NASH patients
were randomly assigned to a diet of 1400 kcal/d and vitamin
E, with or without orlistat (which inhibits fat absorption),

and had paired liver biopsies 36 wk after random assignment
(45). The orlistat did not enhance weight loss or improve
histology, NASs, or liver enzymes (45). However, in the
stratiﬁed analysis according to weight loss, patients who
had a $5% total body weight loss had improvements in insulin sensitivity, adiponectin concentrations, and hepatic
steatosis and lower NASs compared with those who did
not have weight loss (45). In another randomized controlled
trial, 31 individuals who had biopsy-proven NASH were
randomly assigned to 48 wk of intensive lifestyle intervention (LS) compared with structured education (control). A
higher of proportion of patients in the LS group had more
significant weight loss (9.3% compared with 0.2%, respectively, P = 0.003) and improved NASs (46). A significantly
larger proportion of the patients in the LS group (72%)
had achieved their primary endpoint (reduction in NAS
$3 or NAS #2) than did those in the control group (30%)
(P = 0.03) (46).

Weight Loss in NAFLD
Dietary intervention has been shown to improve NAFLD in
randomized controlled trials (45, 46). NAFLD patients
with a larger percentage of weight loss were observed to
have more NAFLD remission (Figure 1) (47). This was illustrated by a randomized controlled trial in Hong Kong, where
154 patients were randomly assigned to either dietitian-led
LS or standard of care for 12 mo (47). The majority of the
patients (97%) in the group who achieved a weight loss of
$10% had NAFLD remission, whereas only 13% of those
who had a weight loss of #3% achieved NAFLD remission
(Figure 1) (47). In the cohort, 64% of the intervention group
compared with 20% of the controls achieved NAFLD remission (95% CI: 30%, 58%; P < 0.001) (47). In the adjusted
multivariate analysis, body weight reduction was the only
independent predictor of NAFLD remission (47). The intervention group also had larger mean decreases in intrahepatic
TG content as measured by proton magnetic resonance
spectroscopy (47). This was further corroborated by another
prospective study in which 293 patients underwent 52 wk
of lifestyle changes and received paired liver biopsies (48).
Ninety percent of patients who were able to achieve
$10% weight loss had resolution of their NASH, and 45%
of patients who achieved that amount of weight loss had
regression of their fibrosis (48). Patients who lost $5% of
their weight had higher rates of NASH resolution (58%)
than did those who lost <5% of their weight (10%; P < 0.001),
and a $2-point improvement in NASs without fibrosis
worsening (82% compared with 32% in those who lost
<5% of their weight; P < 0.001). Hepatic fibrosis either stabilized or improved in patients who were able to achieve
a significant amount of weight loss (the groups that had
>7–10% and $10% weight loss) (Figure 2) (48). Fibrosis
was unchanged or improved in 85 of 88 (95%) patients
who achieved $5% weight loss, in contrast to 162 of 205
(79%) individuals without this extent of weight loss. However, most of the patients with worsening fibrosis [43 of
46 (93%)] were associated with little or no weight reduction

FIGURE 1 NAFLD patients (n = 154) randomly assigned to a
dietitian-led lifestyle modification compared with standard of
care for 12 mo. The figure represents the percentage of patients
who had NAFLD resolution according to the percentage of weight
loss when compared with their baseline. P-trend , 0.001. NAFLD,
nonalcoholic fatty liver disease. Adapted from reference 47 with
permission.

(<5%) (48). In the small number of patients who had worsening fibrosis in the setting of weight loss, this could be reflective of a liver biopsy sampling error. Regardless, overall,
the data suggests that a higher amount of weight loss is associated with higher rates of NASH resolution and fibrosis
improvement.

Different Diets in NAFLD
Dietary salt in NAFLD. Animal studies have shown
that a high-sodium diet is associated with obesity and
visceral adipose hypertrophy, as well as increased leptin
concentrations (49). The adipocytes taken from rats on a
high-sodium diet were observed to have the increased
ability to convert glucose into lipids (49). Rats fed a highsodium diet (91 mg sodium $ kg21 body weight $ d21)
had increased hepatic steatosis, serum FFAs, insulin concentrations, and TGs (50). Further associations between a
high-sodium diet and NAFLD were observed in clinical
studies. In a Korean study of 100,177 patients, men and
women who consumed a higher-sodium diet had an
increased prevalence of NAFLD (51). In this study, patients
were given questionnaires that quantified their sodium
intake and were divided into quintile groups, and NAFLD
Nutritional approaches for weight loss in NAFLD 255

FIGURE 2 NASH patients (n = 293) who underwent 52 wk of
lifestyle changes. This figure represents hepatic fibrosis
stabilization, regression, or worsening according to the
percentage of weight loss from baseline to 52 wk. P = 0.04.
NASH, nonalcoholic steatohepatitis. Adapted from reference 48
with permission.

was diagnosed by ultrasound and exclusion of chronic
alcohol use ($20 g/d in women and $30 g/d in men).
Men and women who were in the top quintile group for
consuming sodium (mean sodium intake of 3485 mg/d
in men and 3310 mg/d in women) had an increased
prevalence of NAFLD, by 25% and 32%, respectively
[prevalence ratio (PR) = 1.25; 95% CI: 1.18, 1.32;
P < 0.001 and PR = 1.32; 95% CI: 1.18, 1.47; P < 0.001,
respectively] compared with sodium users in the lower
quintile group. In another Chinese study, patients in the
high-salt quartile group had an increased prevalence of
NAFLD compared with patients in the lowest quartile
group (37.5% compared with 28%, P < 0.05) (52).
However, in a multivariable analysis that adjusted for BMI,
there was no association of NAFLD with a high-salt diet,
which suggests that the association between salt and NAFLD
may still be secondary to obesity (52). Only subjects in the
highest quartile of regular animal food pattern consumers
were associated with NAFLD (HR: 1.35; 95% CI: 1.063,
1.724; P < 0.05) compared with subjects in the lowest
quartile. However, the limitations of the study include the
lack of objective definition of a high-salt diet, with patients
being categorized into the high-salt diet group if they were
noted to have consumed large amounts of rice, pickled
vegetables, processed meat, bacon, salted duck eggs and
fish, and tea.
Furthermore, studies have suggested that the Dietary Approaches to Stop Hypertension (DASH) diet is associated
with a lower prevalence of and improvement in NAFLD.
In a randomized controlled trial, 60 NAFLD subjects
256 Hsu et al.

(diagnosed by ultrasound and elevated liver enzymes) were
randomly assigned to either the DASH diet or control diet
for 8 wk (53). DASH is a sodium-restricted (<2400 mg/d)
diet rich in vegetables, fruits, whole grains, and low-fat dairy,
and low in saturated fats, cholesterol, refined grains, and
sweets. Both groups were calorie-restricted to 350–700 kcal
less than the computed energy requirement and had a diet
composed of 52–55% carbohydrates, 16–18% proteins, and
30% total fats, but the DASH diet had a higher content of
fruits, vegetables, and whole grains (53). Initial and followup ultrasounds showed that more patients in the DASH
diet group (80% compared with 43.3%, P = 0.003) had a decreased NAFLD grade by ultrasound (53). Patients in the
DASH diet group also had more significant decreases in their
BMI, insulin and ALT concentrations, serum TGs, and total–
to–HDL cholesterol ratio (53). This suggests that caloric restriction alone may be inadequate and that diet type may
be more important in improving liver enzymes and hepatic
steatosis. In a separate smaller case-control study, patients
who adhered to the DASH diet in the top quartile group
were 30% less likely to have NAFLD (HR: 0.70; 95% CI:
0.61, 0.80) (54). However, the results of this study may be
of less significance given the small numbers (102 patients),
and the association was not significant after adjusting for confounders such as dyslipidemia and BMI. Because the DASH
diet has been shown to have benefits that include lowering
cardiovascular disease risk and hypertension, we advise that
patients with NAFLD or NASH attempt to adhere to a lowsodium diet (55).

Carbohydrates and fat in NAFLD. High-carbohydrate
(speciﬁcally fructose or sucrose) and high-fat (HF) diets have
been implicated in the development of NAFLD in animal
studies (56–58). In a study of Wistar rats that were fed either
an HF diet (45% fat and 34.1% carbohydrate), a control diet
(57.9% carbohydrates and 13.4% fat), or a high-sucrose diet
(20% sucrose in drinking water, 57.9% carbohydrates, and
13.4% fat) for 12 wk, rats consuming the HF diet had developed grade 2–3 steatosis in 34–66% of their hepatocytes,
whereas rats consuming the high-sucrose diet had developed
grade 1–3 steatosis in 5–33% of their hepatocytes (56). None
of the controls developed steatosis (56). Fructose alone has
been implicated in the development of NAFLD and severe
hepatic fibrosis in NAFLD in animal studies (57–59). Rats
fed an HF diet (58% fat) and a high-fat, high-carbohydrate
(HFHC) diet (58% fat, 42 g carbohydrates/L drinking water
with a 55% fructose and 45% sucrose solution) gained more
weight, consumed more calories, and had increased fasting
glucose and insulin concentrations (57). In addition, rats fed
HF and HFHC diets had increased hepatic steatosis, liver
weights, hepatic TGs, and ALT concentrations compared
with controls (57). However, only rats consuming the HFHC
diet developed perisinusoidal and periportal fibrosis (57).
The high-fructose diet caused NAFLD and fibrosis by increasing reactive oxygen species, inflammatory macrophages, and
hepatic stellate cell activation (when mRNA levels of a-smooth
muscle actin were measured), and increased concentrations

of plasma coenzyme Q9 (57). Plasma coenzyme Q is important in the mitochondrial respiratory chain and in
mitochondrial ATP production, which is needed for
fructose metabolism (57). In the first step of fructose
metabolism, fructose is first phosphorylated to fructose-1phosphate by means of fructokinase with the use of a substrate
ATP (60). NASH has been associated with mitochondrial
damage and ATP depletion (61).
However, the proposed mechanism by which fructose
causes NAFLD in animal studies remains to be further elucidated and may be multifactorial. Both animal studies and
clinical studies show that high fructose intake can cause
NAFLD by increasing intestinal permeability and endotoxinemia, and decreasing Lactobacillus and Bifidobacterium in
the gut flora (62–64). There is increasing evidence that increased intestinal permeability and bacterial overgrowth
is important in the pathogenesis of NAFLD (65, 66). Gut
microflora–derived bacterial products (such as LPS) activate
hepatic toll-like receptors (TLRs), which then activate an inflammatory cascade that contributes to the pathogenesis
of NAFLD in animal models (67, 68). Mice deficient in
TLR-4 and myeloid differentiation factor 2 (downstream inflammatory cascade of TLR-4) that were fed a methionine
choline–deficient diet (a dietary model of NASH) had less
evidence of NASH, hepatic fibrosis, and hepatic TGs
(68). In addition, TLR-4 deficient mice fed a fructosecontaining diet (30% fructose water for 8 wk) had decreased
hepatic TG accumulation by almost 40% compared with
fructose-fed wild-type mice (63). The TLR-4–deficient mice
that were fed fructose also had less hepatic lipid peroxidation
and less activation of inflammatory pathways, or less myeloid
differentiation primary response gene 88 (Myd88) and TNF-a
expression, compared with the wild-type mice that were fed
fructose (63). This suggests the importance of TLR-4 in the
role of pathogenesis of NAFLD.
NAFLD is associated with increased intestinal permeability and bacterial endotoxins in both animal and clinical
studies. In fructose-fed mice (30% fructose water for
8 wk), plasma obtained from the portal vein demonstrated
increased bacterial endotoxin concentrations by almost
40% compared with control, and antibiotics attenuated
this effect (62). In this study, fructose-fed mice had increased
hepatic lipids and TGs by almost 8-fold and 4-fold, respectively, compared with controls. A high-fructose diet was also
associated with increased TNF-a expression and increase lipid
peroxidation (increased 4-hydroxynoneal adducts and IĸB expression) (62). In mice fed a high-fructose diet and antibiotics,
hepatic lipid and TG accumulation significantly decreased by
55% and 48%, respectively, and portal vein endotoxin concentration decreased by 40%, which is similar to concentrations
in the control mice (62). This was further observed in clinical
studies; high fructose intake was also associated with increased
portal vein endotoxins in NAFLD patients. In a pediatric
cohort study, obese Hispanic adolescents with hepatic steatosis
(magnetic resonance spectroscopy >5%), were noted to have
increased plasma bacterial endotoxin concentrations compared with those without NAFLD. NAFLD adolescents who

were also provided high-fructose beverages at 3 meals/d for
4 wk had higher plasma endotoxin concentrations at weeks
2 and 4 compared with adolescents who received highglucose beverages (64). Although these were short-term studies, it is quite notable that the consumption of fructose was
associated with transient increases in plasma endotoxin,
and further studies are needed to delineate the gut microflora of patients consuming a diet that includes highfructose corn syrup. In animal studies, probiotics such as
lactobacillus have attenuated the NAFLD induced by a fructose diet. Mice fed lactobacillus and a fructose diet had a
portal ALT that was almost normalized, and this was associated with less hepatic steatosis and TNF-a expression
(69–71).
High fructose consumption has been associated with increased severity of hepatic ﬁbrosis in NAFLD patients. In the
NASH Clinical Research Network, 427 NAFLD subjects were
enrolled in a study that required a food questionnaire data
and a follow-up liver biopsy after 3 mo (72). After researchers controlled for age, sex, BMI, and total caloric intake, daily fructose consumption was associated with a
lower steatosis grade, but a higher ﬁbrosis grade. In older
patients ($48 y of age), fructose consumption was associated with increased hepatic inflammation and hepatocyte
ballooning (72). Surprisingly, minimal-to-moderate consumers of fructose had lower fasting serum glucose and
TGs and a better insulin sensitivity profile than those not
consuming fructose (72). However, the authors concluded
that these appreciable differences in insulin sensitivity
were related to lifestyle changes patients pursued after enrolling in the trial. They also concluded that fructose consumption is a modifiable risk factor in preventing the
progression of NAFLD and the increased risk of hepatic
fibrosis. In addition, 47 patients with NAFLD (without
cirrhosis) with paired liver biopsies and dietary questionnaires were compared with 24 controls, and there was a
2- to 3-fold higher consumption of high-fructose corn
syrup–related food products (carbonated beverages, artificially sweetened drinks, baked goods, candies, canned fruits,
jams, and dairy products) in patients with NAFLD (60). Patients with NAFLD had a higher daily consumption of highfructose corn syrup beverages than did control patients (365
compared with 170 kcal/d, P < 0.05) and higher mRNA
levels of fructokinase, suggestive of higher fructose metabolism (60). However, in a meta-analysis of 7 isocaloric trials
in which fructose was exchanged for carbohydrates and 6
hypercaloric trials in which fructose was supplemented,
only the fructose-supplemented hypercaloric diets were associated with increases in intrahepatocellular lipids and increased ALT concentrations (73). The isocaloric exchange
of fructose for other carbohydrates did not cause NAFLD;
only excess caloric intake supplemented with fructose was
associated with NAFLD (73). However, the limitation of
the meta-analysis was that it included trials that were short
in duration (#4 wk) and of poor quality (73). In addition,
this meta-analysis did not include trials that evaluated for NAFLD improvement. A randomized controlled
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double-blinded study of 24 overweight Hispanic American
adolescents with NAFLD showed that there was no difference in fructose-only compared with glucose-only beverages
(74). After 4 wk of calorie-matched glucose- or fructoseonly beverages, there was no significant difference in change
in hepatic fat or body weight (74). The glucose-only beverage group did have better adipose insulin sensitivity, decreased circulating concentrations of oxidized LDL, and
decreased plasma FFA (74). Glucose-only beverages
were associated with a better cardiovascular profile than
fructose-only beverages. However, similarly, the limitation
of this study was the short duration, and it would be difficult to ascertain the long-term effects of the chronic consumption of fructose beverages. However, because of the
short duration of fructose consumption in the metaanalysis and randomized controlled trial, it is difficult to
make conclusions that the long-term consumption of fructose would not worsen NAFLD. Thus, based on animal
studies and some of the preliminary clinical studies, we
would advise patients to avoid beverages and diets that
are high in fructose.
Studies do show low-carbohydrate diets to be comparable
with low-fat diets, but many of the studies include lifestyle
changes (e.g., an increase in physical exercise) and hypocaloric diets. One study randomly assigned 54 women
with NAFLD diagnosed by ultrasound and ALT >29 U/mL
to either a low-carbohydrate diet (27% protein, 28% fat,
and 45% carbohydrate) or a low-fat diet (25% protein,
21% fat, <10% saturated fat, and 54% carbohydrate) for
6 mo (75). However, these patients also participated in lifestyle changes that included 1 h of physical exercise 5 d/wk.
The 2 groups lost a similar amount of weight (5.7% and
5.5% of their initial weight, respectively) and received a
mean of 1593 6 82 kcal/d. The decrease in ALT was higher
(41%) in the low-carbohydrate diet group than it was in the
low-fat diet group (33.3%), but whether changes from baseline were significant was not reported (75). The limitation of
the study was that only AST and ALT were measured as primary endpoints, and no follow-up ultrasound was obtained.
Another study randomly assigned 170 overweight and obese
subjects to hypocaloric diets (with a 30% energy reduction)
that were low fat (fat #20% total energy, 0.8 g/kg protein,
and remaining energy from carbohydrates) or low carbohydrate (#90 g carbohydrates, minimum of 30% fat intake,
and 0.8 g/kg protein) for 6 mo (76). These patients did
not necessarily have NAFLD, and only approximately onehalf of the patients had an intrahepatic lipid content
(as measured by MRI spectroscopy, >5.6%) (76). Similar reductions in weight (change in body weight of 7.5 6 0.6
compared with 6.5 6 0.7 kg, P = 0.25), intrahepatic fat
(measured by MRI spectroscopy), abdominal visceral fat,
TGs, FFAs, and HDL were observed with both the low-fat
and low-carbohydrate diets (76). Intrahepatic fat decreased
by a significant 47% in the reduced-carbohydrate group
and by 42% in the reduced-fat group (76). Abdominal visceral fat mass decreased significantly by 22% in the former
and by a similar 21% in the latter group (76). Another study
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also randomly assigned 52 obese patients (not patients with
NAFLD) to hypocaloric (reduction of 750 kcal/d) low-fat
(60% carbohydrate and 25% fat) or low-carbohydrate
(40% carbohydrate and 45% fat) diets for 4 mo, and showed
the low carbohydrate diet to be associated with greater reductions in ALT (29.5 6 9.4 U/L) when compared with
the low-fat diet (24.2 6 8.3 U/L; P < 0.01), and this remained significant even when adjusted for weight loss, baseline ALT concentration, age, and sex (77). However, the
2 groups lost similar amounts of weight [7.0 6 3.8 and
5.7 6 4.1 kg, respectively, relative to baseline (P < 0.001)]
(77). These studies either restrict subjects to hypocaloric
diets or require them to engage in lifestyle changes (physical
exercise) in addition to the low-carbohydrate or low-fat diet.
It is difficult to ascertain whether the metabolic improvements are secondary to weight loss or secondary to the specific macronutrients. In one small pilot study, 4 of 5 NASH
patients who underwent a 6 mo low-carbohydrate ketogenic
diet that was not restricted in caloric intake and not accompanied by an exercise program had improvements in hepatic
steatosis, necroinflammatory grade, and fibrosis at their
follow-up biopsy (78). The diet limited carbohydrate intake
to <20 g/d, without meat or egg intake or caloric restrictions. One patient in this study had worsening steatohepatitis, but this was attributed to nonadherence to the dietary
recommendations and lack of weight loss. Regardless, if
consuming a low-fat or low-carbohydrate diet can lead to
substantial reductions in weight loss, and weight loss is
shown to be beneficial in NAFLD, patients should be advised
to try such diets.

Mediterranean diet and NAFLD. The Mediterranean diet
has been associated with overall decreased mortality and decreased cancer incidence and cardiovascular events (79). A
pilot study compared the Mediterranean diet with a lowfat, high-carbohydrate diet in 12 patients with NAFLD
who underwent a 6-wk crossover intervention study (80).
The Mediterranean diet is mostly composed of vegetables,
whole grains, and fruit, with increased intake of legumes,
raw unsalted nuts, and oily ﬁsh (81). In the pilot study,
patients then underwent a 3-h hyperinsulinemic-euglycemic
clamp study to determine insulin resistance, and hepatic
steatosis was measured by magnetic resonance spectroscopy
(80). A signiﬁcant relative reduction in hepatic steatosis
and improvement in insulin sensitivity was observed in the
patients who followed the Mediterranean diet compared
with those on a low-fat, high-carbohydrate diet (39% 6 4%
compared with 7% 6 3%, respectively, P = 0.012) (80).
Based on this pilot study, a larger randomized controlled
trial called the Mediterranean Dietary Intervention for
Adults with Non Alcoholic Fatty Liver Disease is now
underway and currently enrolling patients until 2017
(81). This was further corroborated by another study in
which NASH patients were noted to have lower adherence
to the Mediterranean diet than were NAFLD patients (82).
Seventy-three NAFLD patients (diagnosed by elevated ALT
and hepatic steatosis on an ultrasound) participated

in an FFQ over 12 mo and then crossmatched to healthy
controls (82). Adherence to the Mediterranean Diet was
measured by the MedDietScore (range 0–55) (82). Liver
biopsies were available in 34 of the 73 NAFLD patients,
with 68% of the patients classified as having NASH and
32% classified as having NAFLD (82). The MedDietScore
negatively correlated with serum ALT (P = 0.03), insulin
concentrations (P = 0.001), and steatosis severity (P = 0.006),
and positively correlated with serum adiponectin concentrations (P = 0.04) (82). Patients with NASH were
noted to have a lower adherence to the Mediterranean
diet than were NAFLD patients (29.3 6 3.2 compared
with 34.1 6 4.4, P = 0.004), and were associated with
higher abdominal fat and a higher BMI (82). In a logistic
regression analysis, a 1-unit increase in the MedDietScore
was associated with a 36% lower likelihood of having
NASH (OR: 0.64; 95% CI: 0.45, 0.92; P = 0.02) even
after adjusting for sex and abdominal fat (82). These are
promising preliminary studies that the Mediterranean
diet could improve NAFLD and prevent NASH and hepatic
fibrosis.
The Mediterranean diet is rich in olive oil, or MUFAs,
and improvements in NAFLD may be due to MUFAs or
PUFAs content. Animal studies have shown that oils high
in MUFAs or PUFAs have attenuated the effects of dietaryinduced NAFLD. Mice that were fed an HF diet (49% energy
from fat) for 12 wk and fed phenol-rich extra virgin olive oil
(41.7% energy from olive oil) had an improved lipid proﬁle,
decreased visceral adipocyte inﬂammatory cytokine expression, and improved NASs compared with mice fed an HF
diet without extra virgin olive oil (83). The mean NAS of
mice fed the HF diet was >4, whereas mice fed the extra virgin
olive oil and phenol-rich extra virgin olive oil had NASs of 3
and 2, respectively (83). In addition, menhaden oil, which is
rich in PUFAs such as EPA (20:5n–3) and DHA (22:6n–3),
has been shown to improve the hepatic damage induced
by a high-fat, high-cholesterol (HFHCH) diet in both wildtype mice and genetic animal models of hyperlidemia (84).
In wild-type and LDL-receptor knockout (Ldlr2/2) mice
(the genetic model of hyperlipidemia) fed an HFHCH diet
supplemented with olive oil or menhaden oil for 12 wk,
the addition of menhaden oil decreased liver enzymes and
hepatic TGs to concentrations similar to controls, and reduced
markers of hepatic inflammation and fibrosis when compared
with olive oil (84). Mice consuming an HFHCH diet supplemented with olive oil still had hepatic steatosis, increased liver
enzymes, increased body weight, and increased expression
of markers of inflammation and fibrosis (84). The discrepancy can be explained by the percentage of energy from olive oil. In the first mouse study, 41.7% of the energy was
from olive oil, whereas in the second study, PUFA content
was 2% of the total energy. However, a subsequent mouse
study from the same group that used Ldlr2/2 mice fed a
Western-type diet showed that olive oil, DHA alone, EPA
alone, or EPA and DHA supplementation for 16 wk significantly attenuated the Western diet–induced NASH phenotype and decreased markers of inflammation, fibrosis, and

oxidative stress (85). Further clinical studies will be needed
to extrapolate this data to humans, but given the initial
promising results from the Mediterranean diet, it seems
consistent that MUFAs and PUFAs may have some beneficial effects on NAFLD.

High-protein diet and NAFLD. A mouse study showed
that a high-protein diet (35% protein and 42% fat)
prevented mice from gaining total body weight and the
epididymal fat pad associated with an HF diet (86).
Although the high-protein diet did not decrease liver
weights overall, it did decrease hepatic FFAs, total
cholesterol, and phospholipid content, and the hepatic
lipid content for mice on the high protein diet was only
35–40% than that of lipid content for mice on the low
protein diet in mice on the high-protein diet (86). Mice
on the high-protein diet had elevated mRNA expression
of Pgc1a (PPAR gamma co-activator 1-a) which is a
coactivator of the Pparg (PPAR gamma) receptor involved
in hepatic mitochondrial FA oxidation, oxidative phosphorylation, and gluconeogenesis (86). The high-protein diet was
associated with increased import and oxidation of FAs into
the hepatic mitochondria (86). Interestingly, mice on
the high-protein diet did not have increased plasma
amino acids, but had elevated plasma BCAAs, which was
thought to be important in protein catabolism. A rat
study showed that a high-protein diet (52.4% protein)
reduced the adiposity that was gained from a highsucrose (39.8% carbohydrate and 9.4% fat) and HF, highsucrose diet (33.1% fat and 14.4% carbohydrate) by 20%
(87). In addition, the high-protein diet was associated
with decreased markers of lipogenesis [mRNA expression of FA synthase, acetyl-CoA carboxylase a (Acaa),
acetyl-CoA carboxylase b (Acab), and sterol regulatory
element binding transcription factor 1c (Srebf-1c)] and
increased ketogenesis (elevated b-hydroxybutyrate concentrations) (87). More recently, in a prospective study of 37
NAFLD patients with type 2 diabetes placed on an
isocaloric diet (30% protein, 40% carbohydrates, and 30%
fat) with high animal or plant protein for 6 wk, the highprotein diet was associated with significant 36–48%
reductions in hepatic steatosis by measurement with MRI
spectroscopy (animal protein diet, P = 0.0002; plant
protein diet, P = 0.001) (88). Both groups had decreased
BMI, visceral adipose tissue, liver enzymes, plasma FFAs,
and insulin and glucose concentrations (88). Again, with
both high-protein diets, free amino acid concentrations
were unchanged after the diet, but the animal-protein diet
was associated with higher postprandial concentrations of
BCAAs and methionine, suggestive of increased amino
acid catabolism in skeletal muscle and liver (88). Both
high-protein diets also significantly decreased serum
concentrations of fibroblast growth factor 21 (FGF21) and
decreased FGF21 receptor cofactor klotho b expression in
adipose tissue (88). Elevated FGF21 is associated with
NAFLD and is positively correlated with intrahepatic TG
content (89, 90). FGF21 is predominantly synthesized in
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the liver, and the influx of FFAs from adipose tissue induces
FGF21 receptor expression (90). The FGF21 receptor then
decreases serum FFAs by inhibiting visceral adipose from
undergoing further lipolysis, inhibiting further hepatic TG
synthesis, and promoting FFA oxidation and ketogenesis
(90). Another smaller prospective study of 60 patients
showed that a hypocaloric (1000 kcal/d) high-protein diet
(41% protein, 29% carbohydrate, 24% fat, and 6% fiber)
decreased liver stiffness, alkaline phosphatase, g-glutamyl
transferase, lipid concentrations, and controlled attenuation
parameters, or measurements of hepatic steatosis through
transient elastography, by 14.0% (P < 0.001) (91). Thus,
these studies are promising, but participants were only
given a high-protein diet for short duration of time. Thus,
more studies would be needed to assess the long-term effects
of a high-protein diet, because a high-protein diet can worsen
chronic kidney disease (92).

Various individual food sources and NAFLD. Studies
show that broccoli protects against the development of
NAFLD and liver adenomas in mice fed an HF diet and treated
with diethylnitrosamine (an agent that induces hepatocellular carcinoma in mice). Mice fed an HF diet (19% fat and
31% sucrose) and 10% broccoli had decreased liver weight,
hepatic TGs, plasma ALT concentrations, and number of
liver nodules and adenomas compared with mice fed an
HF diet without broccoli (93). In this study, mice were
started on a Western diet and 10% broccoli at 5 wk before
induction with diethylnitrosamine at 6 wk (93). A subsequent study from the same group again showed that broccoli
attenuated the NAFLD effects of the Western diet (94).
However, in the second mouse study, the broccoli did not
slow down hepatocarcinogenesis, but mice were induced
with diethylnitrosamine at a younger age (2 wk) and before
the administration of broccoli and the Western diet (4 wk to
7 mo) (94). Based on these studies, broccoli can attenuate
the effects of NAFLD in mouse models, minimizing the
risk that they develop liver adenomas, but not necessarily alter the course of hepatocarcinogenesis. However, more clinical studies would be needed to extrapolate this preliminary
data to humans.
Various other supplements, such as ginger, ﬂaxseed,
and green tea extracts, have been explored to improve
NAFLD. In a smaller clinical study of 50 patients, ﬂaxseed supplementation (30 g/d for 12 wk), in addition
to lifestyle modiﬁcations, decreased AST and ALT and
hepatic ﬁbrosis and steatosis scores (as measured by
transient elastography with controlled attenuation parameter measurements) (95). In a separate study of 44
patients, patients were randomly assigned to 12 wk of
2 g ginger supplementation/d or placebo, and ginger
supplementation improved liver enzymes and hepatic
steatosis, but not ﬁbrosis scores (measured by transient
elastography) (96). Finally, 80 participants were randomly assigned to green tea extract (500 mg/d) for
90 d or placebo, and green tea extracts were noted to improve liver enzymes (97). In this study, there was no
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follow-up ultrasound to determine whether there was
improvement in hepatic steatosis; thus, it is unclear
whether the green tea extract had improved hepatic inﬂammation alone or had improved the hepatic steatosis.
The limitations of these clinical studies are their small
size and short duration of supplementation. This data
would have to be further corroborated by larger studies
with long-term follow-up.

Surgical Weight Loss in NASH and NAFLD
The prevalence of NAFLD and NASH is particularly high in
morbidly obese patients. In a review of 12 observational cohorts of morbidly obese patients [BMI (kg/m2) >40 or >35
with a serious comorbid condition], the prevalence of
NAFLD, NASH, and cirrhosis was 91%, 37%, and 1.7%, respectively (29). According to the NIH Consensus Development Conference on Gastrointestinal Surgery for Severe
Obesity (1991), indications for gastrointestinal surgery
include a BMI >40 or BMI >35 with serious cardiopulmonary complications such as type 2 diabetes, obstructive sleep
apnea, hypertension, and cardiomyopathy (98). These patients should also be aged 18–60 y, be an acceptable surgical
risk, and also have a history of multiple failed weight loss attempts (98).
Bariatric surgeries include restrictive procedures such
as vertical banded gastroplasty (VBG), laparoscopic adjustable gastric banding (LAGB), and laparoscopic sleeve
gastrectomy (LSG), whereas restrictive and malabsorptive
procedures include Roux-en-Y gastric bypass (RYGB),
biliopancreatic diversion (BPD), and BPD with duodenal
switch (42, 99). Bariatric surgery has been shown to decrease overall mortality by decreasing the incidence of
cardiovascular disease, malignancy, and diabetes (100,
101). Obese Swedish subjects who underwent bariatric
surgery had decreased overall mortality (HR: 0.71, P = 0.01)
secondary to decreases in cancer- and cardiac-related deaths
(100). Mean weight loss was highest for gastric bypass
(25% 6 11% from baseline), followed by VBG and banding
(16% 6 11% and 14% 6 14%, respectively) after 10 y (100).
Another large retrospective US study showed a 40% reduction (HR: 0.60; 95% CI: 0.45, 0.67; P < 0.001) in overall
mortality in those who underwent RYGB (102). A subanalysis of nondiabetic obese Swedish subjects showed that bariatric surgery decreased the overall incidence of diabetes
(HR: 0.17; 95% CI: 013, 0.21; P < 0.001) (101). A more recent randomized trial compared RYGB, LAGB, and LS in a
3-y follow-up of obese (BMI 30–40) subjects with type 2 diabetes, and showed that gastric surgery, in addition to LS,
had higher rates of achieving complete or partial remission
of diabetes (40% for RYGB and 29% for LAGB) than did LSs
alone (0% for LSs) (103).
Most studies have shown that bariatric surgery, predominantly RYGB, improves hepatic steatosis and steatohepatitis, but they have reported variability in the improvement of
hepatic ﬁbrosis (104–107). In 109 morbidly obese patients
who underwent bariatric surgery, NASH disappeared in
85% of the patients (n = 70, 95% CI: 75.8, 92.2), along

with there being significant improvements in BMI, liver enzymes, insulin resistance profile, and fasting blood glucose
(108). In this cohort, 64.2% (70) had gastric bypass, 29.4%
(32) had gastric banding, 5.6% (6) had sleeve gastrectomies,
and 1 had a biliointestinal bypass. Patients underwent a nutrition program prior to surgery, but it was not mentioned
that they continued intensive lifestyle intervention after surgery. However, notably, patients with persistent NASH after
1 y had less significant weight loss and a worse insulin resistance profile than did those with NASH resolution (mean 6
SD BMI decrease of 9.1 6 1.5 compared with 12.3 6 0.6, respectively; P = 0.005) (109). In addition, patients with gastric
banding tended to have less weight loss and worse NASs. This
suggests that NASH improvement is correlated with sustained
weight loss, and it stresses the importance of nutritional approaches in conjunction with gastric surgery. In this study,
hepatic fibrosis was reduced in only 33.8% of the subjects
(95% CI: 23.6, 45.2), and most patients (85%) had a METAVIR
F0 to F2 fibrosis score (108). This is similar to other studies,
in which less than one-half of the patients had fibrosis improvement after gastric surgery; however, the follow-up
time was only 1 y, and fibrosis resolution could take longer.
Thus, it is difficult to ascertain the effects of bariatric surgery
on fibrosis resolution. In another study of 70 patients who
underwent bariatric surgery (43 with RYGB, 23 with LSG,
and 6 with LAGB) with paired liver biopsies, subjects had improvement in steatosis, inflammation, and fibrosis after surgery (105). However, only 20% of the patients had fibrosis
resolution and 2 cirrhosis patients did not have improvements in their hepatic fibrosis. Similar to the previous
study, the majority of the patients (84.3%) had METAVIR
F0 to F2 fibrosis scores. Again, the mean follow-up was
only 15 6 9 mo between paired liver biopsies. Thus, with
longer-term follow-up, there may be a higher percentage of
patients with fibrosis resolution. In this study, RYGB subjects
had more weight loss and hepatic histologic improvements
than did those who underwent restrictive procedures (93%
of RYGB patients compared with 66% patients of restrictive
procedures had improvement in hepatic histological grade;
P = 0.004). Weight loss again correlated to the degree of hepatic histologic improvement, suggestive of the importance of
maintained weight loss even after gastric surgery and potentially the importance of lifestyle intervention. More recently,
LSG was compared with intragastric balloon placement and
LS alone in obese adolescents during a 1-y follow up, and
there was more significant weight loss in patients who underwent LSG than in those who used any of the other measures
(LSG subjects lost 21.5% of baseline body weight; those who
used intragastric balloons lost 3.4%, and those who underwent LSs lost 1.7%). NASH was resolved in 100% of LSG patients (n = 20) and in only 24% of intragastric balloon
patients (n = 20), whereas fibrosis was resolved in 90% of
LSG patients (all with a METAVIR F2 fibrosis score) and
37% of the intragastric balloon patients. None of the patients
who had LS alone had significant improvements in fibrosis or
NASH. Again, the reduction in NASs correlated with the degree of weight loss and improvements in insulin resistance.

Although the numbers are small but similar to other studies,
this study suggests the importance of degree of weight loss
correlating to improvement in NASH and fibrosis.
In another study with morbidly obese patients (mean 6
SD BMI: 52.8 6 1), 51 patients underwent VBG. Although
84–86% had improvement in their steatosis and steatohepatitis scores, only 47% had improvement in their hepatic fibrosis scores. In fact, 11.7% also had worsening hepatic
fibrosis, whereas 41.1% remained unchanged. Grade 3 steatosis and steatohepatitis were present in 98% of the subjects,
and 84.3% had METAVIR F0 to F2 fibrosis scores. Patients
in this study were placed on a special liquid diet of 655 calories (61.4 g protein, 91.2 g carbohydrates, and 4.9 g fat),
which was distributed in 5 meals for the first 3 mo after
VBG, and placed on regular diet afterwards. Thus, longterm nutritional approaches were not used in conjunction
with gastric surgery. A meta-analysis showed bariatric surgery to have a beneficial effect overall on hepatic histology,
with the observed pooled proportion of patients with improvement or resolution of steatohepatitis at 81.3% (95%
CI: 61.9%, 94.9%). For fibrosis, this was 65.5% (95% CI:
38.2%, 88.1%) (109). However, only 5 of 15 studies had
paired liver biopsies in which fibrosis could be evaluated;
thus, assessment of fibrosis was more limited. The variability
of fibrosis improvement suggests a more permanent liver
damage that may take longer periods of time to reverse
than described in these studies. In addition, there may also
be certain time points at which fibrosis is not reversible.
Therefore, more biomarkers are needed to determine which
type of patients would or would not have fibrosis reversal
with gastric surgery.
Although there are certain beneﬁts to gastric surgery, obese
patients are at increased risk of nutritional or vitamin deﬁciencies preoperatively and postoperatively (110, 111). Preoperatively, most obese subjects are already at risk of vitamin D
deﬁciency secondary to a sedentary lifestyle, lack of sun exposure, and vitamin D sequestration in adipose tissue (111).
Moreover, hyperinsulinemia is associated with increased urinary excretion of zinc, and obesity-related chronic inﬂammation induces hepcidin production, which blocks iron
absorption in duodenum (111). In an observational cohort
of 318 RYGB patients, 12 mo after surgery, the incidence of
postoperative vitamin A deﬁciency was 11%, that of vitamin
C was 34.6%, and that of 25-hydroxyvitamin D was 7%.
Those of vitamin B-1, vitamin B-2, and vitamin B-12 were
18.3%, 13.6%, and 3.6%, respectively (112). In addition, various studies have compared RYGB to BPD with duodenal
switch (113, 114). Although patients who underwent BPD
had more weight loss and more signiﬁcant reductions in total
cholesterol and LDL compared with those undergoing RYGB,
they were also at increased risk of 25-hydroxyvitamin D
and vitamin A deﬁciency, and had an increased number of
follow-up operations related to the initial gastric surgery
(113, 114). Both groups had similar remission rates of diabetes, metabolic syndrome, and changes in blood pressure (113).
Thus, the beneﬁts of gastric surgery in improving NASH and
NAFLD would have to be outweighed against the potential
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long-term nutritional deﬁciencies and side effects. We would
advise patients to pursue LAGB, LSG, or RYGB, over BPD.
However, the long-term beneﬁts of improving hepatic ﬁbrosis
would need to be furthermore clariﬁed in future studies.

Conclusion
Obesity is a rising epidemic and is central to the pathogenesis
of NAFLD and NASH. Insulin resistance is the ﬁrst step in
NAFLD, leading to an imbalance of hepatic lipid metabolism,
which then leads to oxidative stress, lipotoxicity, hepatic inﬂammation, apoptosis, and hepatic ﬁbrogenesis. Cardiovascular disease is often the most common cause of mortality
in NAFLD patients, but NASH patients have increased
liver-speciﬁc mortality. Weight loss and dietary intervention
has been shown in randomized controlled trials to improve
NAFLD and NASH, with the larger beneﬁt seen with larger
amounts of weight loss (>5%). High-salt and high-fructose
diets have been implicated in the development of NAFLD
and associated with the increased prevalence of NAFLD in
clinical studies. The DASH and Mediterranean diets have
proven to be promising in the improvement of hepatic
steatosis. Thus, NAFLD patients should pursue any of the
dietary approaches and adhere to a low-sodium and lowfructose diet. Bariatric surgery is often effective in patients with morbid obesity in improving hepatic steatosis
and steatohepatitis, but its effects have been variable in
improving hepatic fibrosis. More studies are needed to
compare various diets and their impacts on NASH
and obesity-related disease complications in long-term
follow-ups.
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